SCHEMBL6033033

SCHEMBL6033033

[CH2][C@H](CO)c1ccc(Cl)cc1Cl

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TP53 P04637 3/20 0.47
LMNA P02545 2/20 0.47
HTT P42858 1/20 0.47
TSHR P16473 3/20 0.40
HSD17B10 Q99714 2/20 0.40
ADRA2C P18825 1/20 0.40
IDO1 P14902 2/20 0.38
TDO2 P48775 1/20 0.38
KMT2A Q03164 2/20 0.37
ATM Q13315 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
ALDH1A1 P00352 2/20 0.36
MAPK1 P28482 1/20 0.36
HIF1A Q16665 1/20 0.36
MEN1 O00255 1/20 0.36
CYP3A4 P08684 2/20 0.35
TDP1 Q9NUW8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16954723 0.84 ALDH1A1 (0.40) TP53LMNAHTTTSHRHSD17B10
SCHEMBL5000481 0.80 TP53 (0.52) TP53LMNAHTTTSHRADRA2C
SCHEMBL16953064 0.79 GABRA1 (0.42) TP53LMNAHTTTSHRKMT2A
SCHEMBL8395600 0.79 TP53 (0.50) TP53LMNAHTTTSHRHSD17B10
SCHEMBL16953761 0.78 PSEN1 (0.39) LMNAHTTADRA2CIDO1KMT2A
SCHEMBL7460990 0.78 TP53 (0.48) TP53LMNAHTTTSHRHSD17B10
SCHEMBL11452909 0.78 ADRA2C (0.51) TP53LMNAHTTTSHRHSD17B10
SCHEMBL7456749 0.78 TP53 (0.48) TP53LMNAHTTTSHRHSD17B10
SCHEMBL7453698 0.78 ADRA2C (0.51) TP53LMNAHTTTSHRHSD17B10
SCHEMBL4069342 0.78 TP53 (0.48) TP53LMNAHTTTSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1732919-A1 SUBSTITUTED THIOPHENE DERIVATIVES AS ANTI-CANCER AGENTS CHIRON CORPORATION (US) 2006-12-20 EP claimed
WO-2005095386-A1 SUBSTITUTED THIOPHENE DERIVATIVES AS ANTI-CANCER AGENTS CHIRON CORPORATION (US) 2005-10-13 WO claimed